Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression
Katharina Hochheiser, Christoph Heuser, Torsten A. Krause, Simon Teteris, Anissa Ilias, Christina Weisheit, Florian Hoss, André P. Tittel, Percy A. Knolle, Ulf Panzer, Daniel R. Engel, Pierre-Louis Tharaux, Christian Kurts
Katharina Hochheiser, Christoph Heuser, Torsten A. Krause, Simon Teteris, Anissa Ilias, Christina Weisheit, Florian Hoss, André P. Tittel, Percy A. Knolle, Ulf Panzer, Daniel R. Engel, Pierre-Louis Tharaux, Christian Kurts
View: Text | PDF
Research Article Nephrology

Exclusive CX3CR1 dependence of kidney DCs impacts glomerulonephritis progression

  • Text
  • PDF
Abstract

DCs and macrophages both express the chemokine receptor CX3CR1. Here we demonstrate that its ligand, CX3CL1, is highly expressed in the murine kidney and intestine. CX3CR1 deficiency markedly reduced DC numbers in the healthy and inflamed kidney cortex, and to a lesser degree in the kidney medulla and intestine, but not in other organs. CX3CR1 also promoted influx of DC precursors in crescentic glomerulonephritis, a DC-dependent aggressive type of nephritis. Disease severity was strongly attenuated in CX3CR1-deficient mice. Primarily CX3CR1-dependent DCs in the kidney cortex processed antigen for the intrarenal stimulation of T helper cells, a function important for glomerulonephritis progression. In contrast, medullary DCs played a specialized role in inducing innate immunity against bacterial pyelonephritis by recruiting neutrophils through rapid chemokine production. CX3CR1 deficiency had little effect on the immune defense against pyelonephritis, as medullary DCs were less CX3CR1 dependent than cortical DCs and because recruited neutrophils produced chemokines to compensate for the DC paucity. These findings demonstrate that cortical and medullary DCs play specialized roles in their respective kidney compartments. We identify CX3CR1 as a potential therapeutic target in glomerulonephritis that may involve fewer adverse side effects, such as impaired anti-infectious defense or compromised DC functions in other organs.

Authors

Katharina Hochheiser, Christoph Heuser, Torsten A. Krause, Simon Teteris, Anissa Ilias, Christina Weisheit, Florian Hoss, André P. Tittel, Percy A. Knolle, Ulf Panzer, Daniel R. Engel, Pierre-Louis Tharaux, Christian Kurts

×

Figure 8

Medullary DCs do not process antigen for MHC-II presentation.

Options: View larger image (or click on image) Download as PowerPoint
Medullary DCs do not process antigen for MHC-II presentation.
(A) Uptake...
(A) Uptake of fluorescently labeled OVA by sorted CX3CR1+ APCs from kidney cortices (white squares) and medullas (black squares) of healthy CX3CR1GFP/+ reporter mice. Sorted GFP+ cells were incubated with OVA for 20 minutes at 37°C, washed, and analyzed by flow cytometry. (B) Sorted cortical (white bars) and medullary (black bars) DCs from healthy or 10-day nephritic mice were incubated with 10 μg/ml OVA, as in A. MFI of OVA+ cells, reflecting average amount of antigen uptake per cell. (C) Percentage of OVA+ DCs in cortex (white bars) and medulla (black bars) 30 minutes after i.v. injection of fluorescently labeled OVA into healthy or 10-day nephritic mice. (D) Representative FACS plots of the in vivo OVA uptake of cortical and medullary CD45+MHC-II+ cells in healthy or 10-day nephritic mice, 30 minutes after i.v. injection of Alexa Fluor 647–conjugated OVA. (E) MFI of OVA+ cells in cortex and medulla 30 minutes upon i.v. injection of OVA, as in C. (F) MFI of cortical and medullary DCs, indicating cleaved DQ-OVA after 20 minutes of incubation with 200 μg/ml DQ-OVA. (G) Analysis of cleaved DQ-OVA per endocytosed Alexa Fluor 647–conjugated OVA in cortical and medullary DCs, after 3 hours of incubation with 25 μg/ml DQ-OVA and Alexa Fluor 647–conjugated OVA. (H) mRNA for Cathepsin H, invariant chain, and H2-DM in cortical and medullary DCs from 7-day nephritic mice, relative to GAPDH expression. Results represent 2–3 experiments, with 3 to 5 mice per group. Statistical analysis (B–E) by 1-way ANOVA with Bonferroni test or (F and H) by paired Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts